HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer

BACKGROUND: Aberrant activation of the signal transducer and activator of transcription 3 (STAT3) is frequently seen in patients with gastric cancer (GC), and is generally associated with worse prognosis. HJC0152, a novel STAT3 inhibitor, has shown significant anti-tumor effects in several cancers,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiaoxia, Wu, Mengjie, Xu, Zhenzhen, Wang, Haohao, Wang, Haiyong, Yu, Xiongfei, Li, Zhongqi, Teng, Lisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296682/
https://www.ncbi.nlm.nih.gov/pubmed/30588091
http://dx.doi.org/10.2147/CMAR.S188364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296682/
https://www.ncbi.nlm.nih.gov/pubmed/30588091
http://dx.doi.org/10.2147/CMAR.S188364

Ejemplares similares